MHRA
MHRA suspends GMP certificate for Pfizer site in India
August 22, 2016Manufacturing and Production, Sales and Marketing GMP, India, MHRA, Pfizer, ban, facility, import, suspend
The UK’s Medicines and Healthcare Products Agency (MHRA) has recommended that an Indian facility belonging to Pfizer’s Hospira unit be …
MHRA approves Sanofi Pasteur MSD’s four-strain influenza vaccine for UK use
July 25, 2016Manufacturing and Production, Research and Development, Sales and Marketing MHRA, Sanofi pasteur msd, UK, Vaccine, flu, influenza
Sanofi Pasteur MSD has announced the approval of the latest addition to its family of influenza vaccines in the UK: …
MHRA approves new indication for MSD’s Ezetrol
February 26, 2016Medical Communications, Research and Development, Sales and Marketing MHRA, MSD, NICE, ezetrol
The UK’s Medicines and Healthcare products Regulatory Agency (MHRA) has approved a new indication for MSD’s Ezetrol (ezetimibe), making it …
UK lung cancer patients get early access to breakthrough BMS drug
February 5, 2016Research and Development, Sales and Marketing Bristol-Myers Squibb, MHRA, NICE, eams, opdivo
UK lung cancer patients are to get access to Bristol Myers-Squibb’s Opdivo (nivolumab) through the Early Access to Medicines Scheme …
AstraZeneca lung cancer drug clears UK market access hurdle
September 4, 2015Sales and Marketing AZD9291, AstraZeneca, Early Access to Medicines Scheme, MHRA, NSCLC, eams, lung cancer, non-small cell lung cancer
Follow @Pharmafocus
Novartis heart failure drug available via EAMS
September 3, 2015Sales and Marketing Early Access to Medicines Scheme, Entresto, LCZ696, MHRA, Novartis, eams, heart failure, sacubitril/valsartan
Novartis has won the investigational heart failure treatment LCZ696 (sacubitril valsartan) will be available in the UK under the Early …
Opdivo launched in the UK for skin cancer
July 2, 2015Sales and Marketing BMS, Bristol-Myers Squibb, EMA, Early Access to Medicines Scheme, MHRA, eams, melanoma, opdivo, skin cancer
Bristol-Myers Squibb has launched its cancer immunotherapy treatment Opdivo in the UK for patients with advanced skin cancer. Opdivo (nivolumab) …
£15.8 million UK haul of fake drugs
June 19, 2015Manufacturing and Production, Sales and Marketing MHRA, counterfeit, drugs, fake, interpol
Counterfeit and unlicensed medicines and devices worth £15.8 million have been seized in the UK as part of a global …
Novartis heart drug steps closer to EAMS scheme
April 23, 2015Sales and Marketing LCZ696, MHRA, Medicines and Healthcare products Regulatory Agency, NICE, eams, pim, sacubitril/valsartan
Novartis’ investigational heart failure drug LCZ696 has been handed a Promising Innovative Medicine designation (PIM) after showing that it significantly …
Novartis in major oncology drive
March 30, 2015Research and Development, Sales and Marketing Cancer, FDA, MHRA, Novartis, aduro, ceritinib, eams, early access, zykadia
Novartis says it is ‘stepping up its efforts’ in cancer by launching major initiatives to discover new treatments to combat …
FDA gives new safety warning on Pfizer’s Champix
March 10, 2015Manufacturing and Production, Sales and Marketing Champix, Cochrane, FDA, MHRA, Pfizer, varenicline
The FDA has warned that Pfizer’s stop smoking drug Champix is linked with seizures, aggressive behaviour and blackouts. In its …
Chair appointed for new MHRA devices committee
February 20, 2015Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing MHRA, Peter Nightingale, deac
Dr Peter Nightingale has been appointed as chairman of the Medicines and Healthcare products Regulatory Agency’s (MHRA) newly-formed Devices Expert …
Websites selling illegal drugs increasingly face closure
February 12, 2015Manufacturing and Production, Medical Communications, Sales and Marketing MHRA, counterfeit, drugs, illegal, on tap, websites
The number of websites shut down by the MHRA for selling illegal pharmaceutical products has increased dramatically in recent years, …
MHRA shuts down unlicensed cancer drug facility
February 9, 2015Manufacturing and Production, Sales and Marketing Cambridge, GcMAF, MHRA, first immune, globulin component macrophage activating factor
The MHRA has shut down an unlicensed Cambridgeshire plant that was producing a potentially dangerous drug to be sold online. …
Genentech makes $10m gene testing outlay
January 8, 2015Medical Communications, Research and Development, Sales and Marketing 23andME, DNA, Genentech, MHRA, Pfizer, Roche
Genentech has thrown its weight behind the contentious DNA testing company 23andMe, by agreeing a deal to buy the genomic …
Latest content
Five Facts about NHS and primary care
AI in pharma: From lab development to patient impact
